Palazzo LL, et al. - Among 9,900 patients with stage IV non–small cell lung cancer (NSCLC) diagnosed at age 65 or older, researchers retrospectively focused on disparities and trends in genetic testing and treatment with erlotinib. These participants were identified from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Via logistic regression analyses, they investigated factors related to odds of receiving a genetic test and erlotinib treatment, as well as analyzed trends in these variations by diagnosis year. For patients who did not receive genetic testing, an association of race and sex with rates of erlotinib treatment was observed. For those who did receive testing, a link between low-income status and treatment rates was identified. Over time, no changes were evident in the racial disparity, while the income-based difference grew larger.